Cerus Corporation (CERS) Deep Dive Video

Summary

Cerus is building the case for a universal pathogen-reduced blood standard—near-term cash-flow momentum is real, but the RBC trial is the decisive catalyst.

View CERS stock page · Read the CERS research report

Loading the video player…